Show simple item record

dc.contributor.authorPrice, R N*
dc.contributor.authorDorsey, G*
dc.contributor.authorAshley, E A*
dc.contributor.authorBarnes, K I*
dc.contributor.authorBaird, J K*
dc.contributor.authord'Alessandro, U*
dc.contributor.authorGuerin, P J*
dc.contributor.authorLaufer, M K*
dc.contributor.authorNaidoo, I*
dc.contributor.authorNosten, F*
dc.contributor.authorOlliaro, P*
dc.contributor.authorPlowe, C V*
dc.contributor.authorRingwald, P*
dc.contributor.authorSibley, C H*
dc.contributor.authorStepniewska, K*
dc.contributor.authorWhite, N J*
dc.date.accessioned2009-03-06T15:48:57Z
dc.date.available2009-03-06T15:48:57Z
dc.date.issued2007
dc.date.submitted2009-03-04
dc.identifier.citationWorld Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. 2007, 6:119 Malar. J.en
dc.identifier.issn1475-2875
dc.identifier.pmid17822532
dc.identifier.doi10.1186/1475-2875-6-119
dc.identifier.urihttp://hdl.handle.net/10144/52693
dc.description.abstractThe proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed.
dc.description.sponsorshipEpicentreen
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.malariajournal.comen
dc.rightsPublished by BioMed Central, [url]http://www.malariajournal.com/[/url] Archived on this site by Open Access permissionen
dc.subject.meshAntimalarialsen
dc.subject.meshClinical Trials as Topicen
dc.subject.meshDatabases as Topicen
dc.subject.meshDrug Resistance, Multipleen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshHumansen
dc.subject.meshInterneten
dc.subject.meshMalariaen
dc.subject.meshSurvival Analysisen
dc.subject.meshTreatment Outcomeen
dc.subject.meshWorld Healthen
dc.titleWorld Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs.en
dc.typeArticleen
dc.contributor.departmentInternational Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia. ricprice@doctors.org.uken
dc.identifier.journalMalaria Journalen
refterms.dateFOA2019-03-04T12:17:45Z
html.description.abstractThe proliferation of antimalarial drug trials in the last ten years provides the opportunity to launch a concerted global surveillance effort to monitor antimalarial drug efficacy. The diversity of clinical study designs and analytical methods undermines the current ability to achieve this. The proposed World Antimalarial Resistance Network (WARN) aims to establish a comprehensive clinical database from which standardised estimates of antimalarial efficacy can be derived and monitored over time from diverse geographical and endemic regions. The emphasis of this initiative is on five key variables which define the therapeutic response. Ensuring that these data are collected at the individual patient level in a consistent format will facilitate better data management and analytical practices, and ensure that clinical data can be readily collated and made amenable for pooled analyses. Such an approach, if widely adopted will permit accurate and timely recognition of trends in drug efficacy. This will guide not only appropriate interventions to deal with established multidrug resistant strains of malaria, but also facilitate prompt action when new strains of drug resistant plasmodia first emerge. A comprehensive global database incorporating the key determinants of the clinical response with in vitro, molecular and pharmacokinetic parameters will bring together relevant data on host, drug and parasite factors that are fundamental contributors to treatment efficacy. This resource will help guide rational drug policies that optimize antimalarial drug use, in the hope that the emergence and spread of resistance to new drugs can be, if not prevented, at least delayed.


Files in this item

Thumbnail
Name:
389_world antimalarial.pdf
Size:
254.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record